Abstract:Background: Decision-making for early (Stages 1-3) breast cancer (eBC) care is complex and highly personal, requiring discussions between patients and multiple physicians. Shared decision-making (SDM) is an accepted process that combines input from both patients and physicians, although its overall use is low due to a lack of time and incentives, complicated application techniques, and few communication tools. Reviews show that SDM results in "improved affective-cognitive outcomes" but evidence linking to patient outcomes is sparse. Consequently, patients often receive mixed messages and feel anxious when making treatment decisions. SimBioSys (SBS) developed the TumorSight(TM) platform for individualized treatment planning, coordinated care, and SDM. The first application on this platform, TumorSight Viz, rapidly builds 3D computational models from standard breast MRI data, and further integrates deep learning, genomic/genetic testing, metabolomics, and clinical and demographic data to tailor these models for each individual diagnosed with eBC. The platform can also transform acquired data (e.g., prone) to surgical position (e.g., supine) to create realistic images for precision surgical planning and tools for better SDM with eBC patients. We are assessing how surgeons and patient advocates (PA) perceive TumorSight, and how it may support better SDM and treatment implementation. Methods: SBS conducted an exploratory survey with 31 eBC surgeons to assess the utility of TumorSight Viz visualizations across a range of didactic and planning applications and to query preferences for future components like predicted response to chemotherapy and immunotherapy. Questions were developed with input from breast surgeon advisors. More exploration on TumorSight Viz utility is planned with semi-structured qualitative interviews to assess patient advocates' perceptions of 3D visualizations, surgical planning, and ability to support decision making. PAs will represent geographic, experience, and race/ethnicity diversity. Questions to elicit patient needs, perception of SBS tools, and quality-of-life are being finalized with academic advisors. These will also be used to develop a future eBC patient survey. Results: The SBS surgeon survey revealed that 96% of breast surgeons find visualization important to surgical planning, and these depictions were considered to be critical by a third of breast surgeons surveyed. 96% also listed the conversion of prone to supine visualizations as important (45% critical, 35% valuable, 16% nice to have, 0% not important) for surgical planning value. Surgeons also assigned strong utility for: Graphical 3D rotation to determine tumor shape, size, location, positioning, and landmarks relative to other breast structures – 100% Ability to instantly provide tumor-to-breast volume determination with high accuracy – 96% Ability to instantly provide anticipated tumor extirpation volume to breast volume with high accuracy – 96% Automatic tumor-to-landmark structures measurements (nipple, chest, skin) – 96% Visualization of tumor in the context of other anatomical structures (e.g., skin, blood vessels, chest, heart) – 87% Initial PA discussions (n=3) listed the importance of individualized treatment based on evidence instead of hunches; reasons to avoid prophylactic mastectomies; and ways to lower patient anxiety. Conclusions: Survey-based feedback shows value to eBC surgeons and patients to coordinate care and personalize approaches for optimal outcomes. Computational tools can facilitate patient understanding and patient-tailored treatment. Additional surveys are planned with patients and eBC patient advocacy groups to assess the utility and potential expansion of patient-specific 3D tumor visualizations, both of which will be further discussed. Citation Format: Deborah Collyar, Matthew Biancalana, Anuja Antony, Nicole Liadis, Jyoti Palaniappan, Rebecca Seago-Coyle. Personalized 3D tumor models drive shared decision-making in early breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO2-03-01.

Visual pathology reports for improved collaboration at multidisciplinary head and neck tumor board

Improving Interdisciplinary Communication and Pathology Reporting for Head and Neck Cancer Resections: 3D Visualizations and Margin Reconciliation

Visual pathology reports for communication of final margin status in laryngeal cancer surgery

Evaluation of microscopic disease in oral tongue cancer using whole-mount histopathologic techniques: implications for the management of head-and-neck cancers

Analysis and impact of a multidisciplinary lymphoma virtual tumor board

Concordance of Whole-Slide Imaging and Conventional Light Microscopy for Assessment of Pathologic Response Following Neoadjuvant Therapy for Lung Cancer

Abstract 4973: Impact of technology on quality of thoracic multidisciplinary cancer conferences

Technology enhanced multidisciplinary cancer conferences in gynecologic oncology.

Implementation of a virtual tumor board through VA National TeleOncology service.

Data Visualization Support for Tumor Boards and Clinical Oncology: Protocol for a Scoping Review

Tumor Board Visualization: Integrating Clinical and Laboratory Insights

Virtual easy-to-access hematology tumor boards: Scaling disease expertise across multiple sites of care across urban and rural Tennessee.

Virtual Tumor Mapping: A New Standard for Surgeon–Pathologist Collaboration in Treating Oral Squamous Cell Carcinoma

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center

Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

Can a Digital Tool Improve the Understanding of Treatment Option for Patients With Head/Neck Cancer and Increase Providers' Self-perceived Ability to Communicate With Patients?

Abstract PO2-03-01: Personalized 3D tumor models drive shared decision-making in early breast cancer

Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study

Clinician Perspectives Regarding the Impact of Information Technology on Multidisciplinary Tumor Boards: A National Comprehensive Cancer Network Survey

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Integrating Functional Protein Drug Target Data into a Precision Oncology Molecular Tumor Board